Table 2 Correlation of EZH2 gain to clinicopathologic features of BRAF V600E mutated melanomas
Clinicopathologic feature | EZH2 gain | ||
|---|---|---|---|
Positive | Negative | P valuea | |
Age (year) | 51.5 ± 12.6 | 51.4 ± 13.0 | 0.312 |
Gender N (%) | Â | Â | 0.553 |
 Man | 19 (47.5) | 52 (53.1) |  |
 Female | 21 (52.5) | 46 (46.9) |  |
Thickness (mm) | Â | Â | 0.907 |
 < 1 | 0 (0.0) | 0 (0.0) |  |
 1–2 | 3 (27.3) | 12 (27.3) |  |
 2–4 | 6 (38.6) | 17 (38.6) |  |
 > 4 | 5 (34.1) | 15 (34.1) |  |
Ulceration N (%) | Â | Â | 0.001 |
 Yes | 12 (35.3) | 60 (69.0) |  |
 No | 22 (64.7) | 27 (31.0) |  |
Primary site N (%) | Â | Â | 0.503 |
 Acral | 9 (22.5) | 32 (32.7) |  |
 Mucosal | 7 (17.5) | 11 (11.2) |  |
 CSD | 9 (22.5) | 27 (27.6) |  |
 Non-CSD | 13 (32.5) | 26 (26.5) |  |
 Unknown primary | 2 (5.0) | 2 (2.0) |  |
TNM stage N (%) | Â | Â | 0.071 |
 I | 4 (10.0) | 3 (3.1) |  |
 II | 5 (12.5) | 29 (29.6) |  |
 III | 17 (42.5) | 31 (31.6) |  |
 IV | 14 (35.0) | 35 (35.7) |  |